The metabolism of arachidonic acid by either the cyclooxygenase (COX) or lipoxygenase (LOX) pathway generates eicosanoids, which have been implicated in the pathogenesis of a variety of human diseases, including cancer. It is now considered that they play important roles in tumor promotion, progression, and metastasis, also, the involvement of COX and LOX expression and function in tumor growth and metastasis has been reported in human tumor cell lines. In this study, we examined the expression of COX and LOX in human urological tumors (renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer) by immunohistochemistry and RT-PCR, and we also examined the effects of COX and LOX (5-and 12-LOX) inhibitors in those cells by MTT assay, hoechest staining, and fl ow cytometry. COX-2, 5-LOX and 12-LOX expressions were signifi cantly more extensive and intense in malignant tissues than in normal tissues. Furthermore, 5-LOX inhibitor induced the reduction of malignant cell viability through early apoptosis. These results demonstrated COX-2 and LOX were induced in urological tumors, and 5-LOX inhibitor may mediate potent antiproliferative effects against urological tumors cells. Thus, 5-LOX may become a new target in the treatment of urological tumors.
Introduction
Angiogenetic factors play important roles in urological tumors as well as in other cancers. In recent years, the expression of angiogenic factors in solid human tumors has been widely reported [1] . Growth factors secreted by tumor cells such as fi broblast growth factor, and transforming growth factor, have increased neovascularization in vivo and in vitro [2] . The metabolism of arachidonic acid (AA) by either the cyclooxygenase (COX) pathway or the lipoxygenase (LOX) pathway generates eicosanoids, have been implicated in the pathogenesis of a variety of human diseases, including cancer, and are considered important in tumor promotion, progression, and metastasis.
COX is the fi rst enzyme in the pathway for producing prostaglandin (PG) and thromboxane (Tx) from arachidonic acid, and can occur as three isoforms, COX-1, COX-2 and COX-3. The enzymes of both COX-1 and COX-2 are transformed from the cell membrane phospholipid to arachidonic acid by the phospholipaseA 2 , and then transform arachidonic acid to PGH 2 through PGG 2 (Fig. 1) . COX-1 occurs in tissues and cells and works to protect the cell. COX-2 express momentarily and strongly in response to growth factors and some endotoxins. It is involved with infl ammation, cell proliferation and differentiation [3] . COX-2 has also been shown to play an important role in carcinogenesis. Although the existence of COX-3 has recently been reported, it continues to be argued [4] .
LOX is the fi rst enzyme in the pathway for producing leukotrienes (LT) from arachidonic acid. Isoenzymes of LOX include 5-LOX, 12-LOX and two 15-LOX isoforms (15-LOX-1, 15-LOX-2). These catalyze the biosynthesis of biologically active compounds such as LTs and hydroxyeicosatetraenoic acids (HETEs) [5, 6] . 5-LOX catalyzes the fi rst step in oxygenation of arachidonic acid to produce 5-hydroperoxyeicosatetraenoic acid (5-HPETE), and the subsequent metabolism of 5-HPETE to 5-HETE and LTs (Fig. 1) . LTs belong to an important group of pro-infl ammatory mediators that are synthesized from arachidonic acid via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 , or cysteinyl LTs (LTC 4 , LTD 4 and LTE 4 ) [7] .
The 12-LOX, includes platelet 12-LOX, and leukocyte 12-LOX that oxygenate arachidonic acid at position C-12 to produce 12-hydroperoxyeicosatetra-enoic acid and then 12-HETE [8] . Whereas 5-LOX, 12-LOX and 15-LOX-1, have procarcinogenic roles, 15-LOX-2 appears to have an anti-carcinogenic roles.
Our research focuses on the relationship between COX-2 and LOX (5-and 12-LOX) and urological tumors (renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) and on the antitumor effects of COX and LOX inhibitors.
Methods

Tumor specimens
All tissue specimens were obtained from Osaka City University Hospital. Tumor tissues, nontumor tissues, vascular endothelium, and interstitial tissues from the subjects were preserved in 10% formalin and embedded in paraffi n, serially sectioned onto microscope slides at a thickness of 4 μm.
a) COX
Renal cell carcinoma (RCC) specimens Specimens were obtained from 108 patients with RCC and 20 patients with normal kidney (NK) tissues who underwent total nephroureterectomy due to ureteral cancer. 
Immunohistochemical staining
Immunohistochemical staining was performed with a Vectastain (vector Laboratories, Burlingame, California) avidin-biotin preoxidase complex kit, as previously described [9] . Primary antibodies against rabbit COX-1 (DHHILH-VAVDV) (1:100 dilution in PBS), rabbit COX-2 (LDDINPTVLLKER) (1:100 dilution in PBS), rabbit 5-LOX (Cayman Chemical, Ann Arbor, Michigan) (1:100 dilution in PBS), rabbit 12-LOX (Oxford Biomedical Research, Oxford, Michigan) (1:100 dilution in PBS) and control PBS were used.
Immunohistochemical analysis
Staining was classifi ed into 5 grades from 0 to 4 according to staining intensity and number of positive cells by two blind observers on two separate occasions using coded slides. An average score was calculated. A 4 grade indicated that all staining was maximally intense throughout the specimen, while 0 indicated that staining was absent throughout the specimen. Micro-anatomical staining sites were also recorded. This method was perfomed as previously described [9] . All results are presented as the mean ± SD. Data analysis were performed using ANOVA [10] .
PT-PCR
Concerning COX, total RNA was extracted from RCC, BT, PC and TC tissues. Concerning LOX, total RNA was extracted from RCC tissues, BT and PC cell lines by the acid guanidium thiocyanatephenol-chloroform method [11] . a) COX For Polymerase Chain Reaction (PCR) analysis of RNA, complementary DNA (cDNA) was made by reverse-transcription of 2 μg of each RNA sample using Super Script preamplifi cation system for fi rst-strand cDNA synthesis (GIBCO BRL, MD, U.S.A.). PCR reactions were performed with 3 μl of each cDNA, 3 μl of each sense and antisense primers (20 μM), and 1 unit of Taq polymerase (NIPPON GENE, Toyama, Japan). 35 cycles of denaturation, annealing, and extension (94ºC for 45 sec, 54 ºC for 45 sec, and 72 ºC for 2 min) were performed on automatic heat-block (Model PJ2000 DNA Thermal cycler, PERKIN ELMER, NJ, U.S.A.).
The primers used were: Human COX-1 sense (5'-TGCCC AGCTCCT-GGCCCGCCGCTT-3') and antisense (5'-GTG-CATCAACACAGGCGCCTCTT C-3');
Human COX-2 sense (5'-TTCAAATGAGA-TTGTGGGAAAATTGCT-3') and antisense (5'-AGATCATCTCTGCCTGAGTATCTT-3'); H u m a n g l y c e r a l d e h y d e 3 -p h o s p h a t e dehydrogenase (G3PDH) sense (5'-CCACCCAT-GGCAAATTCCATGGCA-3') and antisense (5'-TCTAGAGGGCAGGTCAGGTCCACC-3').
b) LOX
After the RT reaction, nested PCR was used to examine 5-and 12-LOX mRNA expression. For 5-and 12-LOX, the fi rst run PCR profi le was 94 ºC, 15s to denature; 61 ºC, 30s for annealing and extension for 30 cycles with upstream (5'-CTTCCCGTGCTACCGCTG-3') and downstream (5'-TGGGGTTGGCACCATTGAG-3') primers. 5 μl of fi rst run PCR product was used for the nested PCR with the profi le of 94 ºC, 15s to denature; 61 ºC, 30s for annealing and extension for 25 cycles with nested primers (upstream 5'-CCAG-GAGACAATGCTTTGGACA-3'; downstream 5'-GAACAACTCATCATCCTGCCAG-3'). 
Reagents and materials
Cell cultures
The human RCC cell line (Caki-1) and normal prostate stromal cell were provided by Dr. Shinichi Ikemoto (Dept. of Urology, Osaka City University School of Medicine, Osaka, Japan). The human BT cell line (T24), PC cell lines (PC3, DU-145), TC cell line (NEC-8) and normal proximal tubular endothelial cell (PRTEC) were obtained from Health Science Research Resources Bank (Osaka, Japan). Normal bladder cell line was obtained from the patients with normal bladder tissues who underwent total prostatectomy due to prostate cancer.
Cells were grown in culture flask (Nunc, Roskilde, Denmark) in RPMI 1640 supplemented with 10% FBS, 100 U/ml of penicillin and 100 μg/ ml of streptomycin in a humidifi ed 5% CO 2 atmosphere at 37 ºC. The media were changed every 3 days and the cells were separated via trypsinization, using trypsin/EDTA when they reached subconfl uence. Flow Cytometry (Annexin V and propidium iodide staining)
Cell proliferative studies
The effects of LOX inhibitors on human urological tumors cell lines were determined by dual staining with Annexin V-FITC and propidium iodide using Annexin V-FITC Apoptosis Detection Kit I (Biosiences Pharmingen). Annexin V-FITC and propidium iodide (PI) were added to the cellular suspension as in the manufacturer's instruction, and sample fl uorescence of 1.0 × 10 4 cells was analyzed fl ow cytometry. Flow cytometry was with FACScan (Becton Dickinson, Germany). Cell which were Annexin V-FITC positive and PI negative were identifi ed as early apoptosis. Cell which were Annexin V-FITC positive and PI positive were identified as late apoptosis or necrosis.
Flow Cytometry (Identifi cation of DNA fragmentation)
The assay was performed by TdT-mediated dUTP Nick End Labelling (TUNEL) method using APO-DIRECT TM kit (Becton Dickinson, Germany). 
Detection of apoptosis by Hoechst staining
DNA chromatin morphology was assessed using hoechst staining. Human urological tumors cell (5 × 10 5 cells) were incubated with 50 μM LOX inhibitor for 24 hour. Cells were washed by RPMI-1640 and labeled with 8 mg/ml of hoechest 33342 (Sigma-Aldrich Japan K.K. Tokyo, Japan) for 10 min; PI (Sigma-Aldrich Japan K.K. Tokyo, Japan) was added (10mg/ml fi nal concentration), and the cells were examined by fl uorescence microscopy.
Results
Expression of COX and LOX
1) Immunohistochemistry a) COX
RCC tissue sample COX-2 expression was observed in proximal and distal tubules of NK tissues. However, in epithelial cells, blood vessels and stromal tissues, while COX-2 was not expressed in NK tissues, COX-2 was strongly expressed in all RCC tissues.
BT tissue sample COX-1 was weakly expressed in CC tissues but no expression was found in any BT tissues. On the other hand, COX-2 was strongly expressed in all BT tissues with an intense expression in high-grade BT group. Neither COX-1 nor COX-2 were expressed in NB tissues.
PC tissue sample
The expression of COX-1 was very weak in PC, PIN, BPH and NP tissues. However, COX-2 was strongly expressed in all PC tissues, although very weak expression of COX-2 was found in PIN, BPH and NP tissues.
TC tissue sample
COX-1 and COX-2 were strongly expressed in all TC group tissues, although very weak expression of COX-1 and COX-2 were found in NT tissues.
b) LOX
RCC tissue sample 5-and 12-LOX were strongly expressed in all grades RCC tissues (A: RCC -G1, B: RCC -G2, C: RCC -G3) and other types of RCC tissues (D: RCC papillary cell type, E: RCC chromphobe cell type, F: RCC collecting duct type) although very weak expressions of 5-and 12-LOX were found in NK tissues (G). Immunostaining with PBS was negative (H) (Fig. 2) .
BT tissue sample 5-and 12-LOX were strongly expressed in all grades of BT tissues, although very weak expressions of 5-and 12-LOX were found in CC and NB tissues.
PC tissue sample
5-and 12-LOX were strongly expressed in all grades of PC and PIN tissues, although very weak expressions of 5-and 12-LOX were found in BPH and NP tissues. RCC tissues, and examined them for intensity of COX-2 immunostaining. COX-2 expression score was signifi cantly more extensive and intense in all categories of RCC tissues than NK tissues. COX-2 expression score was higher in G1 cancer than in G3 cancer. However, no difference was seen in all categories among grades. Another comparison between stages, the expression score was higher in early stage cancer pT1 than in advanced cancer (pT2 or above). However, this comparison among stages also shows no signifi cant difference among the categories.
BT tissue sample
We classified 3 categories (epithelium, blood vessel, stromal tissue) in BT tissues, and examined them for intensity of COX-1 and COX-2 immunostaining. COX-2 expression score was signifi cantly more extensive and intense in epithelial cells of BT and CC than in epithelial cells of NB. COX-2 expression score was higher in G3 cancer than in G1 cancer. Moreover, the expression score was higher in advanced cancer (pT2 or above) than in early stage cancer (pT1 or below). On the other hand, no difference was seen in blood vessels and stromal tissues between NB and BT tissues.
PC tissue sample
We classified 3 categories (epithelium, blood vessel, stromal tissue) in PC tissues, and examined them for intensity of COX-1 and COX-2 immunostaining.
COX-2 expression score was signifi cantly more extensive and intense in epithelial cells of all grades PC tissues than in BPH and PIN tissues. On the other hand, COX-2 expression score was high in the blood vessels, and the stromal tissues of PC in the study groups with no signifi cant difference between grades. However, COX-2 expression score in the blood vessels and stromal tissues from BPH, PIN and NP were at basic level.
TC tissue sample
We classified 2 categories (epithelium, blood vessel) in TC tissues, and examined them for intensity of COX-1 and COX-2 immunostaining.
COX-1 expression score was signifi cantly more extensive and intense in all categories of TC tissues than in NT tissues. COX-2 expression score was also signifi cantly more extensive and intense in all categories of TC tissues in the studied groups than in NT tissues. However, there were no signifi cant differences among the five histopathological groups in all categories.
b) LOX RCC tissue sample
We classifi ed 3 categories (epithelium, blood vessel, a small quantity of stromal tissue) in RCC tissues, and examined them for intensity of 5-and 12-LOX immunostaining.
5-and 12-LOX expression scores were signifi cantly more extensive and intense in all categories of RCC tissues than NK tissues. Only in epithelium, 5-and 12-LOX expression scores were higher in G1 cancer than in G3 cancer. However, no differences were seen in blood vessels and stromal tissues among the three grades.
BT tissue sample
We classifi ed 3 categories (epithelium, blood vessel, stromal tissue) in BT tissues, and examined them for intensity of 5-and 12-LOX immunostaining.
5-and 12-LOX expression scores were significantly more extensive and intense in BT tissues than in CC and NB. A signifi cant difference was seen only in epithelium, showing that staining was intensifi ed as the grade increased. No difference was seen in blood vessels and stromal tissues between grades.
Comparison of early and advanced stages shows a signifi cant difference only in epithelium. No difference was seen in blood vessels and stromal tissues between early stage (pT1 or below) and advanced cancer (pT2 or above).
PC tissue sample
We classifi ed 3 categories (epithelium, blood vessel, stromal tissue) in PC tissues, and examined them for intensity of 5-and 12-LOX immunostaining.
5-and 12-LOX expression scores were significantly more extensive and intense in PC and PIN tissues than BPH and NP tissues in all categories. There was no significant difference between grades.
TC tissue sample
We classified 2 categories (epithelium, blood vessel) in TC tissues, and examined them for intensity of 5-and 12-LOX immunostaining.
5-and 12-LOX expression scores were signifi cantly more extensive and intense in all TC groups than NT tissues in all categories. However, there were no signifi cant differences among the fi ve histopathological groups in all categories (Table 1) .
RT-PCR a) COX RCC tissue
We detected a specifi c band of COX-2 mRNA band in RCC, whereas sample of from NK displayed no band of COX-2 mRNA.
BT tissue
We detected specifi c band of COX-1 mRNA in all samples (BT, CC and NB). However, we detected specifi c band of COX-2 in BT, while a weak band was displayed in CC and no clear band was displayed in NB.
PC tissue
We detected a specifi c band of COX-1 mRNA in all samples (PC, BPH and NP). However, we detected a specifi c band of COX-2 was detected in PC, while a weak band was displayed in BPH and no clear band was displayed in NP.
TC tissue
We detected a specifi c band of COX-1 and COX-2 mRNA all TC groups.
b) LOX RCC tissue
We detected a specifi c band of 5-and 12-LOX mRNA in RCC, whereas the sample of from NK displayed no band of-and 12-LOX mRNA.
BT cell line
We detected a specifi c band of 5-and 12-LOX mRNA (A: 5-LOX, B: 12-LOX, lane 2) in BT cell line, whereas the sample of from NB cells displayed no band of-and 12-LOX mRNA (A: 5-LOX, B: 12-LOX, lane 1) (Fig. 3) .
PC cell line
We detected a specifi c band of 5-and 12-LOX mRNA in PC cell line, whereas a sample of from NP cells displayed no band of-and 12-LOX mRNA.
2) Effect of COX and LOX inhibitors MTT assay a) COX RCC cell line
All COX inhibitors were unable to induce a reduction of cell viability with the half-maximal concentration of growth inhibition of RCC cells in the range of 10-80 μM and were unable to stop the growth of RCC cells. All COX inhibitors had no effect on normal proximal tubular endothelial cells (PRTEC) proliferation.
BT cell line
Similar to RCC cells, COX inhibitors could not induce a reduction of cell viability with the halfmaximal concentration of growth inhibition of BT cells in the range of 10-80 μM and could not stop the growth of BT cells. COX inhibitors had no effect on normal bladder cells proliferation.
PC cell line
Similar to RCC and BT cells, none of the COX inhibitors could induce a reduction of cell viability with the half-maximal concentration of growth inhibition of PC cells in the range of 10-80 μM, neither could they stop the growth of PC cells. COX inhibitors had no effect on normal prostate stromal cells proliferation (Table 2) . The dose-response analysis of viability in human prostate cancer and normal prostate stromal cells treated with COX and LOX inhibitors (10-80 μM, 48 hr) was measured by the MTT assay and expressed as% of control culture conditions. the range of 10-80 μM. Although the effect of non-specifi c LOX inhibitor was strongest, the effect of 5-LOX inhibitor was stronger than that of 12-LOX inhibitor. No LOX inhibitors had any effect on normal bladder cells proliferation.
Similar to RCC and BT cells, LOX inhibitors induced a reduction of cell viability with the half-maximal concentration of growth inhibition of PC cells in the range of 10-80 μM. Although the effect of nonspecifi c LOX inhibitor was strongest, the effect of 5-LOX inhibitor was stronger than that of 12-LOX inhibitor. No LOX inhibitors had any effect on normal prostate stromal cells proliferation (Table 2) .
TC cell line
Similar to RCC, BT and PC cells, LOX inhibitors induced a reduction of cell viability with the halfmaximal concentration of growth inhibition of TC cells in the range of 10-80 μM. Although the effect of non-specifi c LOX inhibitor was strongest, the effect of 5-LOX inhibitor was stronger than that of 12-LOX inhibitor.
3) Apoptosis effect of LOX inhibitor a) Flow cytometry RCC cell line
RCC cells treated with 100 μM 5-LOX inhibitor could induce early apoptosis, not late apoptosis or necrosis and DNA fragmentation. However, treated with 100 μM 5-LOX inhibitor did not induce apoptosis in normal proximal tubular endothelial cellss (PRTEC). Diagram of FITCAnnexin V/PI fl ow cytometry (Fig. 4) and typical fl ow cytometry analysis histogram are presented (Fig. 5) .
BT cell line
Similar to RCC cells, BT cells treated with 100 μM 5-LOX inhibitor could induce early apoptosis, not late apoptosis or necrosis and DNA fragmentation. Note: Graded 0 to 4 on the coded sections by two observers in a blinded manner. 0, no staining; 4, maximum intensity. Statistical analysis was performed using the analysis of variance (P value; ANOVA). 5-and 12-LOX immunostaining were more intense and diffuse in testicular tumor tissues than in the normal testicular tissues. p Ͻ 0.001.
5-LOX immunostaining
A B
PC cell line
Similar to RCC and BT cells, PC cells treated with 100 μM 5-LOX inhibitor could induce early apoptosis, not late apoptosis or necrosis and DNA fragmentation.
TC cell line
Similar to RCC, BT and PC cells, TC cells treated with 100 μM 5-LOX inhibitor could induce early apoptosis, not late apoptosis or necrosis and DNA fragmentation.
2) Hoechest staining RCC cell line
RCC cells treated with 50 μM 5-LOX inhibitors caffeic acid, and non-specifi c LOX inhibitor NDGA showed chromatin condensation, cellular shrinkage, small membrane-bound bodies (apoptotic bodies), and cytoplasmic condensation. Cells with 12-LOX inhibitor baicalein showed the same apoptotic changes slightly. In contrast, untreated cells maintained normal chromatin patterns and cell size. 
BT cell line
Similar to RCC cells, BT cells treated with 50 μM 5-LOX inhibitors caffeic acid (B), and non-specifi c LOX inhibitor NDGA (D) showed chromatin condensation, cellular shrinkage, apoptotic bodies, and cytoplasmic condensation. Cells with 12-LOX inhibitor baicalein (C) showed the same apoptotic changes slightly. In contrast, untreated cells maintained normal chromatin patterns and cell size (A) (Fig. 6 ).
PC cell line
Similar to RCC and BT cells, PC cells treated with 50 μM 5-LOX inhibitors caffeic acid, and nonspecifi c LOX inhibitor NDGA showed chromatin condensation, cellular shrinkage, apoptotic bodies, and cytoplasmic condensation. Cells with 12-LOX inhibitor baicalein showed the same apoptotic changes slightly. In contrast, untreated cells maintained normal chromatin patterns and cell size.
TC cell line
Similar to RCC, BT and PC cells, TC cells treated with 50 μM 5-LOX inhibitors caffeic acid, and non-specific LOX inhibitor NDGA showed chromatin condensation, cellular shrinkage, apoptotic bodies, and cytoplasmic condensation. Cells with 12-LOX inhibitor baicalein showed the same apoptotic changes slightly. In contrast, untreated cells maintained normal chromatin patterns and cell size.
Discussion
With recent increases in routine medical check-ups and progress in diagnostic imaging techniques, the discoveries of RCC have risen. The cause of RCC is unknown. RCC generally does not respond well to radiotherapy and chemotherapy compared to many other types of cancers, and anticancer drugs as interleukin-2 is used with relative success. Surgery is currently the only therapeutic option. Hence, new molecular targets are needed for the treatment and prevention of RCC.
The natural history of BT is not well understood, but exposure to carcinogens, including aromatic amines, is considered a major risk factors for the development of BT. Workers exposed to aromatic amines frequently have a mutated p53 gene, a tumor suppressor gene involved in the carcinogenesis of many tumors. PC comprises 32% of all cancers in American men and is on the rise worldwide. Because of increased screening, PC is frequently diagnosed at a clinically localized stage, making it amenable to the therapy. Nevertheless, it remains the second most common cause of cancer death in men. These patients generally respond to androgen deprivation therapy, but the vast majority eventually experience disease progression and become refractory to sustained hormonal manipulation. Typically, such patients progress with a rise in their serum prostatespecific antigen level. Unfortunately, standard therapeutic options at this stage of disease are limited, and while there has been some success with chemotherapy for hormone-refractory PC patients, the response is generally short-lived [12] . TC is very rare with over 90% of all TC being germ cell tumors (seminoma and non-seminoma), and the remaining percentage non-germinal tumors. The survival rate of TC has improved in recent years, refl ecting the development and refi nement of effective combination chemotherapy. However, it is still necessary to improve the treatment of TC.
Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumor effects on human urological tumors (RCC, BT, PC and TC) and have attracted a great deal of attention. The typical target of NSAIDs is COX. In recent reports, a number of patients have had significantly low-risk of colorectal cancer while they continued using NSAIDs typifi ed by aspirin. Consequently, the suppression of carcinogenesis by administering NSAIDs has come into focus. It was also reported that the size and number of adenoma were markedly reduced when sulindac which is a type of NSAIDs was given to patients with the familial adenomatous polyposis, a high risk group for colorectal cancer [13] . Regarding COX-2 in RCC, BT and PC, COX-2 expression in malignant tissues was stronger than that in normal tissues using immunohistochemical staining and RT-PCR [9, 14, 15] .
Both COX-1 and COX-2 expressions in all tissue types of TC were stronger than those in normal tissues using immunohistochemical staining and RT-PCR [16] . Both COX-1 and COX-2 expressions appeared stronger in all tissue types of TC possibly due to the amount of PG increased in TC. Evidence revealed the PG quantity increased in breast cancer tissue compared to normal breast tissue and the expression of both COX-1 and COX-2 increased [17] .
Many publications have reported COX-2 expression in malignant tissue was stronger than in normal tissue, and COX-2 expression in malignant tissue was stronger than COX-1 expression in malignant tissue. However, the correlation between the grade or stage, and COX-2 expression can be argued.
Although many papers have reported NSAIDs produce anti-tumor effects, our studies confi rmed that eight kinds of COX inhibitors were unable to induce reduction of the viability in human urological tumors cells in the range of 10-80 μM by MTT assay [18] .
Our results suggest COX-2 expression is strong in treating urological tumors, but the antitumor effect of COX inhibitor (including COX-2 inhibitor) is very weak in urological tumor patients in a single administration at a clinical dose. COX-2 inhibitor is suitable for chemopreventive therapy.
Regarding 5-and 12-LOX in urological tumors, 5-and 12-LOX expressions in malignant tissues were stronger than those in normal tissues using immunohistochemical staining and RT-PCR [8, [19] [20] [21] . Similar to COX-2, the correlation between the grade or stage, and LOX expression can be argued.
Furthermore, LOX inhibitor (particularly 5-LOX inhibitor) could induce reduction of the viability in human urological tumors cells in the range of 10-80 μM by MTT assay. The effect of 5-LOX inhibitor was stronger than that of 12-LOX inhibitor [22] . Furthermore, urological tumors cells treated with 5-LOX inhibitor could induce early apoptosis and DNA fragmantation in urological tumors cells using fl ow cytometry and hoechest staining.
Several papers have reported LOX inhibitors to be targets for development of new chemopreventive or chemotherapeutic strategies for PC. Ghosh J et al. reported that inhibition of arachidonate 5-LOX triggers massive apoptosis in both androgen-sensitive (LNCaP) and androgenrefractory (PC3) human PC cells [23] . Furthermore, Ghosh J also reported the metabolites of arachidonate 5-LOX promoted survival of PC cells involving down-regulation of stress-activated protein kinase [24] . Pommery N et al. reported dual COX-2/5-LOX inhibitors induced agents potentially useful in PC chemotherapy through apoptosis [25] . Ghosh J also reported the combination of selenium and 5-LOX inhibitors may be a more effective regimen for PC control [26] .
Research strongly suggests LOX expression is strong in urological tumors, but the anti-tumor effect of 5-LOX inhibitor is weak in urological tumor patients receiving a single administration at a clinical dose. 5-LOX inhibitor is suitable as a chemo-preventive therapy.
In conclusion, it is clear that COX-2 and LOX (particularly 5-LOX) are involved in the initiation and promotion of urological tumor tissues. It may be possible to use COX-2 and LOX inhibitors as anti-tumor drugs from the viewpoint of preventing cancer. However, it may be diffi cult to use the COX-2 inhibitor or 5-LOX inhibitor at the clinical dose with expectation of a suppressive effect on the cancer. Although the clinical application of 5-LOX inhibitor requires further research and consideration, the target of 5-LOX is a novel strategy in the treatment of human urological tumors.
